Objectives: The objective of this study was to investigate the antimicrobial activity and specificity of globomycin, an inhibitor of lipoprotein signal peptidase II (LspA), against Mycobacterium tuberculosis.
Introduction
Mycobacterium tuberculosis is among the leading infectious causes of mortality worldwide with 2 million estimated deaths each year. 1 One reason why M. tuberculosis is a serious threat to tuberculosis control programmes is the global prevalence of drug-resistant and multidrug-resistant strains. 2 Drug resistance is a known risk factor for treatment failure, transmission and death. 2, 3 As we shift towards individualized therapies based on the susceptibility profile of each isolate, 4 there is a growing need for new anti-tuberculosis drugs with novel mechanisms of action.
Lipoprotein signal peptidase II (LspA) is a bacterial lipoprotein-processing enzyme that cleaves the signal sequence from prolipoproteins after they are secreted and lipid-modified in the cell wall. 5 We and others have shown that deletion or disruption of lspA in M. tuberculosis results in the severe attenuation of M. tuberculosis in the mouse lung (N. Banaiee, E. Z. Kincaid, S. G. Lin, E. Desmond, W. R. Jacobs and J. D. Ernst, unpublished results). 6 Given the absence of LspA homologues in mammalian cells, the mycobacterial LspA provides an attractive drug target in M. tuberculosis. Globomycin is a peptide antibiotic that is made by several Streptomyces species and inhibits Gram-negative bacteria through the inhibition of LspA. 7 Globomycin derivates have also been shown to have potent activity against Gram-positive bacteria. 8 Thus, it has been proposed that globomycin should be exploited for further drug development against M. tuberculosis. In this report, we investigated the activity and specificity of globomycin against M. tuberculosis. We show that although globomycin kills M. tuberculosis at concentrations of 40 mg/L, it does so independently of LspA.
Materials and methods

Bacteria
All M. tuberculosis strains were grown in shaking cultures at 80 rpm to mid-log phase in Middlebrook 7H9 broth (Difco) supplemented with 0.2% glycerol, 10% OADC and 0.05% Tween 80. Escherichia coli was grown in shaking Luria broth (Difco) cultures.
Antibiotics
Globomycin was kindly provided by Sankyo Co. (Tokyo, Japan) and dissolved in ethanol and used at 10 mg/mL.
Globomycin concentration curves
Bacterial cultures were grown to mid-log phase and diluted in the respective media to an optical density of 0.05 at a wavelength of 600 nm. Globomycin was subsequently added at the indicated concentrations. An equal volume of solvent was used to achieve each drug concentration. At indicated time points, 200 mL of live culture was aseptically removed in duplicate and the optical densities were measured using a SpectraMax 340PC 384 spectrophotometer. When indicated, cultures were also enumerated by serial dilution and plating on Middlebrook 7H9/ ADC agar.
Western blotting
To extract mycobacterial proteins, 1 mL of bacterial culture was sedimented and washed once with 1 mL of PBS and resuspended in 300 mL of extraction buffer (50 mM Tris -HCl pH 7.5, 5 mM EDTA, 0.6% SDS, 10 mM NaPO 4 and Roche Complete Protease Inhibitor Cocktail). The suspension was added to 0.1 mL of 0.1 mm zirconia/silica beads and the tube was vortexed for 5 min and subsequently sedimented for 2 min at 12 600 g. The supernatant was removed and the protein concentration was determined with the BCA protein assay kit (Pierce). A total of 0.3-1.5 mg of protein was separated on a 12% SDS-PAGE gel and immunoblotting was performed as described previously. 9 Polyclonal anti-MPT83 was kindly provided by Dr Harald Gotten Wiker (Gades Institutt, Norway) and incubated overnight at 48C at a dilution of 1:2000.
Results and discussion
Globomycin is mycobactericidal
Globomycin non-competitively inhibits LspA in E. coli, which ultimately results in bacterial killing. 7, 10 To determine the activity of globomycin against M. tuberculosis, we measured the bacterial growth rate with a spectrophotometer at various concentrations of globomycin. As shown in Figure 1(a) , globomycin was found to inhibit bacterial replication at 40 mg/L with complete inhibition occurring at 160 mg/L. When treated bacteria were diluted and enumerated on agar, an approximately 50-fold reduction in viability was observed at 80 mg/L, whereas complete killing occurred at 160 mg/L. Although the bactericidal concentration of globomycin was high in M. tuberculosis, we found that in top 10 E. coli, globomycin was active at 20 mg/L (Figure 1b) .
Mycobactericidal activity of globomycin is LspA-independent
The finding that globomycin kills M. tuberculosis is surprising because mutation of lspA is not lethal in M. tuberculosis. 6, 9 To test the hypothesis that the mycobactericidal activity of globomycin is independent of its effect on LspA, we evaluated lipoprotein processing in M. tuberculosis after treatment with globomycin. As shown in Figure 2 , compared with wildtype and lspA mutant, the signal sequence peptidase activity of M. tuberculosis was unaffected after 6 days of treatment with globomycin at 80 mg/L. Furthermore, to determine whether the activity of globomycin on M. tuberculosis is independent of LspA, we evaluated the replication of M. tuberculosis lspA mutant, 9 which lacks the putative drug target, in the presence and absence of globomycin. If the activity of globomycin on M. tuberculosis were due to specific inhibition of LspA, then we would not expect to see any growth inhibition in the lspA mutant. As shown in Figure 3 , treatment of M. tuberculosis lspA mutant with globomycin resulted in killing, similar to that seen in the wild-type bacteria. Together, these findings unambiguously confirm that globomycin does not inhibit LspA in M. tuberculosis and that the mycobactericidal activity of globomycin against M. tuberculosis is independent of LspA.
Given that LspA is essential for the full virulence of M. tuberculosis in mice, 6 it has been suggested that globomycin should be exploited for further drug development against M. tuberculosis. However, the results presented here show that globomycin lacks any LspA-dependent activity against M. tuberculosis and thus it would not be useful as an inhibitor of LspA in M. tuberculosis. Although globomycin is known to inhibit LspA in Gram-negative and Gram-positive bacteria, its LspA-independent toxicity in these bacteria has not been determined.
